Nicox SA
PAR:COX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nicox SA
Net Income (Common)
Nicox SA
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nicox SA
PAR:COX
|
Net Income (Common)
-€27.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Net Income (Common)
-€115.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-19%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Net Income (Common)
-€86m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-18%
|
|
|
Inventiva SA
PAR:IVA
|
Net Income (Common)
-€354.1m
|
CAGR 3-Years
-87%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Net Income (Common)
-$147.2m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-13%
|
|
|
Abivax SA
PAR:ABVX
|
Net Income (Common)
-€336.1m
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
Nicox SA
Glance View
Nicox SA is an ophthalmology company. The company is headquartered in Valbonne, Paca. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
See Also
What is Nicox SA's Net Income (Common)?
Net Income (Common)
-27.8m
EUR
Based on the financial report for Dec 31, 2022, Nicox SA's Net Income (Common) amounts to -27.8m EUR.
What is Nicox SA's Net Income (Common) growth rate?
Net Income (Common) CAGR 1Y
37%
Over the last year, the Net Income (Common) growth was 37%.
